Literature DB >> 18322219

IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice.

Charles F Anderson1, Rosalia Lira, Shaden Kamhawi, Yasmine Belkaid, Thomas A Wynn, David Sacks.   

Abstract

Leishmania tropica is the causative agent of Old World anthroponotic cutaneous leishmaniasis, which is characterized by lesions that take an extended period of time to heal, often resulting in disfiguring scars, and are more refractory to treatment than leishmaniasis caused by Leishmania major. Immunologic studies involving experimental animal models of L. tropica infection are virtually nonexistent. In the current study, infectious-stage L. tropica were used to establish dermal infections in C57BL/6 and BALB/c mice. In both strains, the lesions were slow to develop and showed minimal pathology. They nonetheless contained a stable number of between 10(4) and 10(5) parasites for over 1 year, which were efficiently picked up by a natural sand fly vector, Phlebotomus sergenti. Control of parasite growth depended on the development of a Th1 response, as C57BL/6 mice genetically deficient in Th1 cytokines and BALB/c mice treated with Abs to IFN-gamma harbored significantly more parasites. By contrast, IL-10-deficient mice harbored significantly fewer parasites throughout the infection. To further study the immunologic mechanisms that may prevent efficient clearance of the parasites, IL-10 and TGF-beta signaling were abrogated during the chronic phase of infection in wild-type C57BL/6 mice. Distinct from chronic L. major infection, IL-10 blockade alone had no effect on L. tropica, but required simultaneous treatment with anti-TGF-beta Abs to promote efficient parasite clearance from the infection site. Thus, chronic infection with L. tropica appears to be established via multiple suppressive factors, which together maintain the host as a long-term reservoir of infection for vector sand flies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322219     DOI: 10.4049/jimmunol.180.6.4090

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

2.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

3.  Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen.

Authors:  R Maurya; R Kumar; V K Prajapati; K D Manandhar; D Sacks; S Sundar; S Nylén
Journal:  Parasite Immunol       Date:  2010-07       Impact factor: 2.280

4.  Brucella alters the immune response in a prpA-dependent manner.

Authors:  Juan M Spera; Diego J Comerci; Juan E Ugalde
Journal:  Microb Pathog       Date:  2014-02-04       Impact factor: 3.738

5.  A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection.

Authors:  Keer Sun; Luisa Torres; Dennis W Metzger
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

6.  Immunopathological characterization of human cutaneous leishmaniasis lesions caused by Leishmania (Viannia) spp. in Amazonian Brazil.

Authors:  Cláudia Maria Castro Gomes; Maria Gloria Teixeira Sousa; Joyce Prieto Bezerra Menezes; Marliane Campos Batista; Ana Carolina Stocco Lima; Walter Belda; Daniel Bradshaw; Monica Elinor Alves Gama; Márcia Dalastra Laurenti; Fernando Tobias Silveira; Carlos Eduardo Pereira Corbett
Journal:  Parasitol Res       Date:  2017-02-21       Impact factor: 2.289

7.  IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis.

Authors:  De'Broski R Herbert; Tatyana Orekov; Charles Perkins; Fred D Finkelman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.

Authors:  Rajesh Kumar; Ram A Bumb; Poonam Salotra
Journal:  Immunology       Date:  2010-01-22       Impact factor: 7.397

10.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.